Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- Immunovant said IMVT-1402 600 mg met the Week 28 ACR20 endpoint in D2T RA (92.5% vs. 75.6% placebo, p=0.0139), plans FDA discussions for later this year, and had $722.3 million in cash and equivalents as of September 30, 2026.
- 10-Q report · filed Nov 9, 2026
- Immunovant reported that IMVT-1402 600 mg met the D2T RA primary endpoint, with 92.5% of participants maintaining ACR20 response at Week 28 versus 75.6% for placebo (p=0.0139); the 300 mg arm did not differ significantly from placebo.
The audio replay and transcript follow the call.